title: Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
abstract: The population pharmacokinetics of subcutaneously administered golimumab (50 mg or 100 mg every 4 weeks) were characterized in patients with active psoriatic arthritis (PsA) in GO-REVEAL, a randomized, double-blind, placebo-controlled, phase 3 study. A total of 2029 serum golimumab concentrations from 337 patients were analyzed using NONMEM. A 1-compartment pharmacokinetic model with first-order absorption and elimination was chosen to describe the observed concentration-time data. For a patient of standard weight (70 kg), the population estimates (typical value +/- standard error) for golimumab pharmacokinetic parameters were as follows: apparent clearance = 1.38 +/- 0.04 L/d, apparent volume of distribution = 24.9 +/- 1.04 L, and absorption rate constant = 0.908 +/- 0.121 per day. The between-subject variability was 37.6% in apparent clearance and 37.9% in apparent volume of distribution. Body weight, antibody-to-golimumab status, baseline C-reactive protein level, and smoking status were identified as significant covariates on apparent clearance. Body weight was also a significant covariate on apparent volume of distribution. None of the concomitant medications examined (methotrexate, corticosteroids, and nonsteroidal anti-inflammatory drugs) were significant covariates on apparent clearance, although the median trough golimumab concentration in patients receiving methotrexate was higher than for those not receiving methotrexate. These significant covariates account for part of the variability in systemic exposure to golimumab observed in patients with PsA.
authors.affiliation: Centocor Research and Development, Malvern, Pennsylvania 19355, USA.
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Xu
authors.forename: Thuy
authors.initials: T
authors.lastname: Vu
authors.forename: Howard
authors.initials: H
authors.lastname: Lee
authors.forename: Chuanpu
authors.initials: C
authors.lastname: Hu
authors.forename: Jie
authors.initials: J
authors.lastname: Ling
authors.forename: Hong
authors.initials: H
authors.lastname: Yan
authors.forename: Daniel
authors.initials: D
authors.lastname: Baker
authors.forename: Anna
authors.initials: A
authors.lastname: Beutler
authors.forename: Charles
authors.initials: C
authors.lastname: Pendley
authors.forename: Carrie
authors.initials: C
authors.lastname: Wagner
authors.forename: Hugh M
authors.initials: HM
authors.lastname: Davis
authors.forename: Honghui
authors.initials: H
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D018501:Antirheumatic Agents / Q000494:pharmacology; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001835:Body Weight; D002097:C-Reactive Protein / Q000378:metabolism; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000494:pharmacology; D008875:Middle Aged; D008954:Models, Biological; D017711:Nonlinear Dynamics; D012907:Smoking / Q000009:adverse effects; D014018:Tissue Distribution; D000079424:Tumor Necrosis Factor Inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000079424:Tumor Necrosis Factor Inhibitors; D002097:C-Reactive Protein; C529000:golimumab; D008727:Methotrexate